Itoh K, Konno T, Sasaki T, Ishiwata S, Ishida N, Misugaki M
Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan.
Clin Chim Acta. 1992 Mar 31;206(3):181-9. doi: 10.1016/0009-8981(92)90087-7.
Urinary levels of pseudouridine and 1-methyladenosine in patients with leukemia and lymphoma were measured by the inhibition ELISA using monoclonal antibodies to determine the correlation of nucleosides excretion with disease activity. Significantly elevated levels of these nucleosides were detected in patients with all types of disease tested. Seventy-seven percent (46/60) and 62% (37/62) of patients had elevated levels of pseudouridine and 1-methyladenosine above normal mean + 2S.D., respectively, and combination assay of these nucleosides gave higher positive rate (87%; 52/60) than either single assay. The changes of urinary pseudouridine and 1-methyladenosine reflected the disease status of patients in remission or in relapse and the effect of chemotherapy. These results suggest that urinary pseudouridine and 1-methyladenosine might be clinically useful as complementary markers to the monitoring of the disease status of patients with leukemia and lymphoma by hematological examination.
采用针对假尿苷和1 - 甲基腺苷的单克隆抗体，通过抑制酶联免疫吸附测定法（ELISA）来检测白血病和淋巴瘤患者尿液中这两种物质的水平，以确定核苷排泄与疾病活动之间的相关性。在所检测的所有类型疾病患者中，均检测到这些核苷水平显著升高。分别有77%（46/60）和62%（37/62）的患者假尿苷和1 - 甲基腺苷水平高于正常均值加2个标准差，并且这两种核苷的联合检测阳性率（87%；52/60）高于单一检测。尿液中假尿苷和1 - 甲基腺苷的变化反映了患者缓解期或复发期的疾病状态以及化疗效果。这些结果表明，尿液中的假尿苷和1 - 甲基腺苷可能在临床上作为补充标志物，通过血液学检查来监测白血病和淋巴瘤患者的疾病状态。
